The PARADIGM-HF and DAPA-HF trials further expanded the treatment landscape with the introduction of angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium–glucose cotransporter 2 (SGLT2) inhibitors [5,6]. Here, SLC5A2 is linked to hydrops fetalis.